EUCTR2008-001382-28-IT进行中（未招募）1 期
A Phase 2, open label, dose regimen ranging clinical study to determine the safety and efficacy of INCB018424 in patients with advanced polycythemia vera or essential thrombocythemia refractory to hydroxyurea - ND
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Must be at least 18 years of age 2. Confirmed diagnosis of polycythemia vera or essential thrombocythemia as determined by treating physician (Guidelines in Appendix 10 and 11) 3. Patients should have disease refractory to hydroxyurea or for whom treatment with hydroxyurea is contraindicated as determined by the treating physician. Disease must be assessed within 21 days prior to treatment initiation. or Patients who have refused further treatment with hydroxyurea due to side effects. These patients must have had a trial with hydroxyurea, and the treating physician must concur that discontinuing hydroxyurea is in the best interest of the patient. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 5. Required baseline laboratory data include: a) Hct > 45% for PV or phlebotomy required two times in prior six months with at least one occurrence in prior three months b) Platelet count ≥ 125 x 109/L for PV patients c) Platelet count > 650 x109/L for ET patients unless receiving treatment d) Absolute neutrophil count (ANC) ≥ 1.2 x 109/L for both patient groups e) Total bilirubin ≤ 2 x institutional upper limit of normal (ULN) for both patient groups f) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN for both patient groups g) Serum creatinine ≤ 2 x ULN for both patient groups 6. Females will be either postmenopausal for at least 1 year with documented follicle stimulating hormone (FSH) > 30 IU/L or surgically sterile for at least 3 months OR females of childbearing potential who agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from Screening through Follow-up. (Note: Permitted methods which are at least 99% effective in preventing pregnancy should be communicated to the subjects and their understanding confirmed). For all females, the urine pregnancy test result must be negative at Screening. Males must agree to take appropriate precautions to avoid fathering a child (with at least 99% certainty) from Screening through Follow-up. (Note: Permitted methods which are at least 99% effective in preventing pregnancy should be communicated to the subjects and their understanding confirmed.) 7. Is able to comprehend and is willing to sign an informed consent form, indicating that the patient is aware of the nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, side effects, risks, and discomfort. 8. Willing and able to comply with scheduled visits, treatment plan and laboratory tests.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Females who are pregnant or are currently breastfeeding 2. Treatment with interferon alpha or anagrelide within 7 days and hydroxyurea within 1 day of starting INCB018424. All other cytoreductive therapies for PV or ET or investigational medications must be discontinued within 28 days of enrollment. 3. Patients diagnosed with another malignancy unless the malignancy was cervical intraepithelial neoplasia or basal or squamous cell skin cancer and the patient has been disease free for > 3 years, unless approved by Sponsor. 4. Patients receiving therapy with intermediate or high dose steroids greater than the equivalent of 10 mg prednisone per day 5. Patients with known active hepatitis A, B, C or known positivity for HIV 6. Uncontrolled inter-current illness or has any concurrent condition that, in the Investigator?s opinion, would jeopardize the safety of the patient or compliance with the protocol. 7. Clinically significant cardiac disease (NYHA Class III or IV) 8. Incomplete recovery from any prior surgical procedures or had surgery within 4 weeks prior to study entry 9. Presence of acute active infection requiring systemic antimicrobials 10. Any current or planned therapy with CYP3A4 inhibitors or inducers unless approved by the Sponsor 11. Prior treatment with any oral JAK inhibitor is not permitted unless agreed to by both the investigator and the Sponsor.
研究者
相似试验
进行中（未招募）
不适用
A Phase IIa, multi-center, open-label, dose ranging study of the efficacy, safety, and tolerability of oral DU-176b administered once or twice daily in the treatment of adult patients undergoing total hip arthroplasty.EUCTR2004-004415-29-LVDaiichi Medical Research Inc402
进行中（未招募）
1 期
A Trial of Lu AG13909 in Adult Participants with Cushing’s DiseaseCushing's DiseaseMedDRA version: 20.0Level: LLTClassification code: 10011651Term: Cushing's disease Class: 10014698CTIS2023-504733-53-00H. Lundbeck A/S18
进行中（未招募）
不适用
A Phase II, open-label, randomised, dose-finding study to compare the efficacy (in terms of clearance of RhD-positive RBCs) and safety of LFB-R593, a monoclonal anti-RhD antibody, vs Rhophylac®, a polyclonal anti-RhD immunoglobulin in healthy RhD negative volunteersProphyllaxis against RhD isoimmunisation during pregnancy (anti-D prophylaxis)Treatment of RhD negative individuals after incompatible transfusions with blood components containing RhD-positive red blood cells.MedDRA version: 9.1Level: LLTClassification code 10019513Term: Hemolytic disease of fetus or newborn, due to isoimmunizationMedDRA version: 9.1Level: LLTClassification code 10044360Term: Transfusion with incompatible bloodEUCTR2009-011017-24-DEFB Biotechnologies
进行中（未招募）
1 期
A Dose Finding Study of Debio 4228 in Participants With Locally Advanced/Metastatic Prostate Cancerlocally advanced/metastatic prostate cancerMedDRA version: 21.1Level: PTClassification code: 10036909Term: Prostate cancer metastatic Class: 100000004864CTIS2024-511038-11-00Debiopharm International SA60
进行中（未招募）
不适用
A phase 2 randomized, controlled, open-label dose-blinded , multi-center, dose-finding study of the safety and efficacy of I-0401 in the treatment of patients with fractures of the tibial plateau requiring grafting. - NDEUCTR2006-003688-30-ITKUROS BIOSURGERY AG180